According to a recent survey, hereditary angioedema is a rare genetic disorder that affects approximately 1 in 50,000 people worldwide. It is characterized by recurrent episodes of swelling in the skin and mucous membranes, which can be painful and potentially life-threatening if they occur in the airways or digestive tract. The condition results from a deficiency or dysfunction of C1 inhibitor protein, which regulates immune system activity and prevents excess fluid from leaking out of blood vessels into surrounding tissues. Symptoms may first appear during childhood or adolescence and often worsen over time without proper treatment. There are currently several medications available to prevent attacks or treat acute symptoms, including plasma-derived C1 inhibitor replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors. However, many patients still struggle to obtain prompt diagnosis and access to these treatments due to limited awareness among healthcare providers and high costs associated with their use. Ongoing research efforts are focused on improving diagnostic accuracy, developing new therapies with longer duration of action or better tolerability profiles than existing options, and exploring potential links between hereditary angioedema and other inflammatory conditions such as autoimmune disease or cancer.
1.
enhancing survivors of brain tumors' quality of life.
2.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
3.
A protein with new anticancer activity has been identified
4.
Studies point to redlining as a 'perfect storm' for breast cancer
5.
Enzalutamide vs Abiraterone: Which is Better for mCSPC?
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care
3.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
4.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
5.
Progressive Strategies in Oncology and Patient Outcomes
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
Managing Common Side Effects During Cancer Treatment
5.
Clinical Insights in Oncology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation